A renal biopsy study of RG-012 Alport patients

Trial Profile

A renal biopsy study of RG-012 Alport patients

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs RG 012 (Primary)
  • Indications Hereditary nephritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Nov 2017 Status changed from planning to recruiting, according to a Regulus Therapeutics media release.
    • 12 May 2017 New trial record
    • 04 May 2017 According to a Regulus Therapeutics media release, the company has selected dose for this trial which is expected to commence mid-2017. Data is anticipated by year-end 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top